Concepedia
Statistics
Publications
6
Citations
271
H-Index
Active since
2022
Affiliations
United States Food and Drug Administration(Current)
Center for Drug Evaluation and Research
Center for Devices and Radiological Health
Yangbing Li is an author at United States Food and Drug Administration.
Publications per year
2022–2024
FDA Approval Summary: Selpercatinib for the Treatment of Advanced <i>RET</i> Fusion-Positive Solid Tumors
Elizabeth S. Duke, Diana Bradford, Michelle Marcovitz et al. · Clinical Cancer Research · 2023 · 71 citations · Full text
FDA Approval Summary: Dabrafenib in Combination with Trametinib for <i>BRAF</i>V600E Mutation–Positive Low-Grade Glioma
Michael I. Barbato, Jeannette Nashed, Diana Bradford et al. · Clinical Cancer Research · 2023 · 59 citations · Full text
FDA Approval Summary: Pemigatinib for Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma with FGFR2 Fusion or Other Rearrangement
Timil H. Patel, Leigh Marcus, M. Naomi Horiba et al. · Clinical Cancer Research · 2022 · 49 citations · Full text
FDA Approval Summary: Amivantamab for the Treatment of Patients with Non–Small Cell Lung Cancer with <i>EGFR</i> Exon 20 Insertion Mutations
Katie Chon, Erin Larkins, Somak Chatterjee et al. · Clinical Cancer Research · 2023 · 48 citations · Full text
FDA Approval Summary: Tucatinib with Trastuzumab for Advanced Unresectable or Metastatic, Chemotherapy Refractory, <i>HER2</i> -Positive <i>RAS</i> Wild-Type Colorectal Cancer
Sandra J. Casak, M. Naomi Horiba, Mengdie Yuan et al. · Clinical Cancer Research · 2023 · 33 citations · Full text
1–5 of 6